Clinical Trials Directory

Trials / Unknown

UnknownNCT05979454

Value of KL-6 in Rheumatoid Arthritis-Associated ILD

Value of Krebs Von Den Lungen-6 Assay in Rheumatoid Artheritis-associated Interstitial Lung Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Detailed description

Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptian Hospitals . Pumlonary involvement is common in rheumatoid arthritis (RA). Interstitial lung disease associated rheumatoid arthritis (ILD-RA) is responsible for significant morbidity and mortality . Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that is found mainly on the surface of type II pneumocytes as well as in bronchiolar epithelial cells . It has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury . Krebs von den Lungen-6 (KL6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. KL6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (IPF) . KL6 was found useful as well in predicting in-hospital mortality in patients with Acute exacerbation of interstitial lung disease (AE-ILD) . KL-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (CTD-ILD). It can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . Its value in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) has not yet been adequately investigated.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTKrebs von den Lungen-6 (KL6)KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).

Timeline

Start date
2023-01-01
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2023-08-07
Last updated
2023-11-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05979454. Inclusion in this directory is not an endorsement.